###begin article-title 0
###xml 45 50 <span type="species:ncbi:9606">Human</span>
CRALBP is a Highly Prevalent Autoantigen for Human Autoimmune Uveitis
###end article-title 0
###begin p 1
Recommended by Eiji Matsuura
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 81 87 <span type="species:ncbi:9796">equine</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 552 557 <span type="species:ncbi:9606">human</span>
###xml 633 638 <span type="species:ncbi:9606">human</span>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 713 720 <span type="species:ncbi:9606">patient</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
###xml 952 957 <span type="species:ncbi:9606">human</span>
Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test whether CRALBP contributes to human autoimmune uveitis, the specificity of antibodies from human uveitis patient's sera was first evaluated in two-dimensional (2D) Western blot analysis. Subsequent identification of the immunoreactive proteins by mass spectrometry resulted in the identification of CRALBP as a putative autoantigen. Additionally, sera from human uveitis and control patients were by Western blot using purified human recombinant CRALBP. Anti-CRALBP autoantibodies occur more frequently () in human uveitis patients than in normal controls. Thirty out of 56 tested uveitis patient's sera contained autoantibodies reactive against CRALBP, compared to only four out of 23 normal control subjects. The presence of CRALBP autoantibodies in 54% of tested uveitis patients supports CRALBP as a possible autoantigen in human autoimmune uveitis.
###end p 3
###begin title 4
1. INTRODUCTION
###end title 4
###begin p 5
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 464 467 464 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 973 974 973 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1101 1102 1101 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1356 1357 1356 1357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1359 1360 1359 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 94 100 <span type="species:ncbi:9796">equine</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
Cellular retinaldehyde binding protein (CRALBP) was recently detected as major autoantigen in equine recurrent uveitis (ERU), a spontaneous model of human uveitis [1]. Similarly to the two other major uveitis autoantigens, S-antigen (S-Ag) [2], and interphotoreceptor retinoid binding protein (IRBP) [3], CRALBP is expressed in both the retina and the pineal gland. CRALBP is a key component of the retinoid visual cycle and participates in the regeneration of 11-cis-retinal after photoisomerization [4]. The protein is expressed abundantly in RPE cells, where many reactions of the rod visual cycle take place. Additionally, it is found in Mueller glial cells, which have been implicated in cone visual pigment regeneration [4]. In addition to the RPE and Mueller glial cells of the retina, CRALBP expression has been reported in the ciliary body, cornea, pineal gland, optic nerve, brain, and the iris [4]. While ligands in nonretinal tissues have yet to be identified [4], the protein interacts in the retina with several proteins supporting retinoid supply and participating in the visual cycle [5]. Mutations in the CRALBP gene have been associated with several autosomal recessive retinal pathologies, including retinitis pigmentosa, retinitis punctata albescens, bothnia dystrophy, fundus albipunctatus, and in the newfoundland rod/cone dystrophy [4, 6].
###end p 5
###begin p 6
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 72 77 <span type="species:ncbi:9796">horse</span>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
###xml 611 616 <span type="species:ncbi:9606">human</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
Recently, CRALBP was identified as a novel autoantigen in a spontaneous horse disease (ERU), which serves as a model for human autoimmune uveitis. Subsequent characterization of ERU cases revealed B- and T-cell autoreactivity to CRALBP and established a link to epitope spreading [1]. Immunization of experimental animals with CRALBP induced uveitis in two different species with typical tissue lesions at CRALBP-expression sites. ERU shares with human uveitis [7, 8] the autoimmune response to at least two different autoantigens, S-Ag and IRBP. The aim of this study was to investigate the immune response of human uveitis patients to the potential autoantigen CRALBP.
###end p 6
###begin title 7
2. MATERIALS AND METHODS
###end title 7
###begin title 8
2.1. Blood samples and donor eyes
###end title 8
###begin p 9
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
Six normal human donor eyes with no clinical signs of uveitis (2 female, 4 male; mean age 46 years) were used for evaluation of CRALBP expression pattern in normal eyes. Sampling was approved by the local ethics committee in compliance with the tenets of the declaration of Helsinki. All donors gave their informed consent. Peripheral blood samples of 56 patients (34 male, 22 female; mean age 36 years; white Europeans) with uveitis and 23 eye-healthy control subjects (7 male, 16 female; mean age 34 years; white Europeans) were used for this study. Uveitis in patients was defined by intraocular inflammatory signs like endothelial precipitates, cells, and haze in anterior chamber and/or vitreous or signs of retinal vasculitis and choroidal or retinal infiltrates.
###end p 9
###begin p 10
After collection of blood, samples were processed immediately and either serum or plasma was stored at 20degreesC until Western blots were performed. Donor eyes were fixed 15-60 hours postmortem in  buffered formalin.
###end p 10
###begin title 11
###xml 36 41 <span type="species:ncbi:9606">human</span>
2.2. Expression and purification of human recombinant CRALBP
###end title 11
###begin p 12
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Limulus</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 42 49 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Human recombinant CRALBP was expressed in E. coli (Invitrogen, Karlsruhe, Germany) and purified on a Nickel agarose column (Qiagen, Hilden, Germany) [9]. Endotoxin was removed on an Endotrap red column (Profos, Regensburg, Germany) and then controlled by a Limulus amebocyte lysate test (Sigma, Deisenhofen, Germany; levels below ). The identity of purified recombinant CRALBP was confirmed by mass spectrometry.
###end p 12
###begin title 13
2.3. Histology and immunostaining
###end title 13
###begin p 14
###xml 163 169 <span type="species:ncbi:9986">rabbit</span>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 277 282 <span type="species:ncbi:9796">horse</span>
###xml 288 293 <span type="species:ncbi:9606">human</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 446 452 <span type="species:ncbi:9986">rabbit</span>
Formalin fixed eyes were embedded in Paraffin (Microm, Walldorf, Germany). Antigen retrieval was performed at 99degreesC for  in  EDTA-NaOH buffer pH 8.8. We used rabbit anti-human Glial fibrillary acidic protein (GFAP; 1:100, Sigma) antiserum to stain Mueller glial cells and horse anti-human recombinant CRALBP antiserum (1:500) to evaluate CRALBP expression in normal human donor eyes. For fluorescence labeling, GFAP was stained with an anti-rabbit IgG antibody coupled to Alexa 568 (1:500, Invitrogen) and CRALBP with an antihorse IgG-FITC antibody (1:200, Sigma). Nuclei were counterstained with DAPI (Invitrogen).
###end p 14
###begin title 15
2.4. Two-dimensional (2D) Western blotting
###end title 15
###begin p 16
###xml 6 12 <span type="species:ncbi:9796">equine</span>
###xml 890 898 <span type="species:ncbi:9606">patients</span>
###xml 994 1000 <span type="species:ncbi:9986">rabbit</span>
###xml 1006 1011 <span type="species:ncbi:9606">human</span>
Fresh equine retinas were immediately stabilized with a protease inhibitor (Complete, Roche, Penzberg, Germany), homogenized, lyophilized, and stored at -80degreesC. For 2D analysis, protein pellets were solubilized in 2D lysis buffer ( urea,  thiourea,  DTE,  CHAPS). Immobiline dry strips pH 3-,  (GE-Healthcare, Freiburg, Germany) were immersed overnight in lysis buffer containing  protein sample, additional  pharmalytes pH 3-10 (GE-Healthcare), and  bromphenole blue. Isoelectric focusing was performed on a Multiphor (GE-Healthcare) for  at 20degreesC, followed by separation on gradient SDS-PAGE gels (9-) at constant  per gel. One set of gels was silver-stained for mass spectrometry and the second transferred onto nitrocellulose membranes (GE-Healthcare) for Western blot analysis. Nitrocellulose membranes were blocked with  PVP in PBS-T () and incubated with sera from uveitis patients and controls (dilution 1:500; overnight at 4degreesC). Autoantibody binding was detected using rabbit anti-human-IgG-HRP (1:4000, ; Biozol, Eching, Germany) and enhanced chemiluminescence (GE-Healthcare). To assign visible spots to those detected on silver-stained gels, we subsequently stained the nitrocellulose membranes with colloidal gold (Fluka, Deisenhofen, Germany).
###end p 16
###begin title 17
2.5. 1D Western blots for detection of anti-CRALBP autoantibodies
###end title 17
###begin p 18
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 330 341 <span type="species:ncbi:3704">horseradish</span>
###xml 394 400 <span type="species:ncbi:9986">rabbit</span>
###xml 406 411 <span type="species:ncbi:9606">human</span>
###xml 588 593 <span type="species:ncbi:9606">human</span>
Purified and LPS-free human recombinant CRALBP ( protein per lane) was applied to  sodium SDS-PAGE and blotted semidry onto nitrocellulose membranes. Nonspecific binding was blocked with  PVP in PBS-T (). Blots were subsequently incubated with sera in PBS-T (dilution 1:500; overnight at 4degreesC) washed and then incubated with horseradish peroxidase-conjugated secondary antibody (1:4000; , rabbit anti-human-IgG-HRP; Biozol). Signals were then detected with ECL (enhanced chemiluminescence) on Hyperfilm ECL (GE Healthcare) according to manufacturer's instructions. A monoclonal anti-human CRALBP antibody (; Cayman, Tallinn, Estonia) was used as a positive control.
###end p 18
###begin title 19
2.6. Image analysis and quantification of signals
###end title 19
###begin p 20
Quantification of Western blot signals was performed by densitometry with ImageQuant TL software (GE Healthcare) after scanning the films on a transmission scanner (ImageScanner II, GE Healthcare). Images of blot signals on x-ray films (/ resolution) were imported to analysis software (Image Quant TL, v2003) and band volume intensities were quantified.
###end p 20
###begin title 21
2.7. Statistical significance
###end title 21
###begin p 22
###xml 198 206 <span type="species:ncbi:9606">patients</span>
The statistical significance of the frequency of CRALBP autoantibodies in uveitis and control groups was evaluated using the chi-square test. Intensities of positive Western blot signals of uveitis patients and negative controls were compared using the student's -test.
###end p 22
###begin title 23
3. RESULTS
###end title 23
###begin title 24
###xml 21 26 <span type="species:ncbi:9606">human</span>
3.1. CRALBP: a novel human uveitis autoantigen
###end title 24
###begin p 25
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 283 294 283 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(a)</xref>
###xml 321 332 321 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(b)</xref>
###xml 447 458 447 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(a)</xref>
###xml 603 614 603 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(a)</xref>
###xml 823 834 823 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(b)</xref>
###xml 89 95 <span type="species:ncbi:9796">horses</span>
###xml 113 119 <span type="species:ncbi:9796">equine</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 235 241 <span type="species:ncbi:9796">equine</span>
###xml 296 302 <span type="species:ncbi:9796">equine</span>
###xml 374 379 <span type="species:ncbi:9606">human</span>
###xml 388 395 <span type="species:ncbi:9606">patient</span>
###xml 402 408 <span type="species:ncbi:9796">equine</span>
###xml 655 660 <span type="species:ncbi:9606">human</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
Autoantibody profiling led to identification of CRALBP as a novel uveitis autoantigen in horses with spontaneous equine recurrent uveitis (ERU) [1]. Sera from human uveitis patients reacted with CRALBP in 2D Western blots using normal equine retinal proteome as a source of antigen (Figure 1(a), equine retinal proteome, Figure 1(b), 2D Western blot incubated with serum of human uveitis patient). The equine retinal proteome was separated by 2D (Figure 1(a), silver staining) over the pH range 3 to 11. Several hundred proteins could be detected as discrete spots using this high-resolution technique (Figure 1(a)). Western blot analysis using sera from human uveitis patients with posterior uveitis followed by mass spectrometric analysis of the immunoreactive 2D gel components resulted in the identification of CRALBP (Figure 1(b), encircled).
###end p 25
###begin title 26
###xml 66 71 <span type="species:ncbi:9606">human</span>
3.2. CRALBP is expressed in Mueller glial cells and RPE in normal human eyes
###end title 26
###begin p 27
###xml 72 83 72 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(c)</xref>
###xml 188 199 188 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(d)</xref>
###xml 376 387 376 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(e)</xref>
###xml 512 523 512 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(f)</xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
Immunohistochemical staining for CRALBP in six normal human donor eyes (Figure 1(c), Normarski image of donor eye number 6) displayed a strong expression of CRALBP in Mueller glial cells (Figure 1(d), green). To confirm this expression, we additionally stained for glial fibrillary acidic protein (GFAP), a class-III intermediate filament that is Mueller glial cell-specific (Figure 1(e), red). Double staining for CRALBP (green) and GFAP (red) confirmed co-localization of both proteins in Mueller glial cells (Figure 1(f), overlay of CRALBP and GFAP expression yellow) but also CRALBP expression in retinal pigment epithelium.
###end p 27
###begin title 28
###xml 64 72 <span type="species:ncbi:9606">patients</span>
3.3. Detection of anti-CRALBP autoantibodies in sera of uveitis patients
###end title 28
###begin p 29
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 578 586 578 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 722 730 722 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
Since access to fresh human retinal specimen for 2D experiments is limited, we confirmed our findings by Western blots using purified human recombinant CRALBP as antigen. The majority of tested patients was CRALBP-autoantibody positive, however at different levels of signal intensities. Representative results for intermediate, strong, and negative blot results are shown in Figure 2 (signal at , intermediate signals lanes 3 and 4, strong signals lanes 6 and 7, negative signals lane 5). A few sera of healthy individuals (controls) also contained anti-CRALBP autoantibodies (Figure 2, lane 1). As positive control, the purified CRALBP preparation was also clearly recognized by a monoclonal human anti-CRALBP antibody (Figure 2, lane 8).
###end p 29
###begin title 30
###xml 76 84 <span type="species:ncbi:9606">patients</span>
3.4. Significant higher prevalence of anti-CRALBP autoantibodies in uveitis patients
###end title 30
###begin p 31
###xml 133 141 133 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 454 462 454 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
Thirty out of 56 tested uveitis patients were CRALBP autoantibody-positive () compared to four out of 23 () normal control subjects (Figure 3, white circles represent individual healthy subjects, grey circles uveitis patients). Quantification of Western blot signals and statistical evaluation with student's -test revealed no difference in binding intensities between the positive uveitis sera compared to autoantibody-positive sera of normal controls (Figure 3, Y-axis: intensity of Western blot signal as quantified with Image Quant TL software). The higher prevalence of anti-CRALBP autoantibodies in human uveitis sera is statistically significant () as evaluated by the chi-square test.
###end p 31
###begin title 32
4. DISCUSSION
###end title 32
###begin p 33
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Most autoimmune diseases display reactivity to multiple autoantigens [10-12]. However, the relative importance of each autoantigen for a specific disease may differ considerably. Autoantigens may appear as a consequence from tissue destruction and thus only represent an epiphenomenon of the pathogenesis, for example, in T-cell-driven diseases. On the other hand, identification of various concurring autoantigens could point to epitope spreading as a pathogenic mechanism in the particular disease [10]. Finally, some autoantigens are useful for predicting individuals at risk for developing the respective autoimmune disease [12].
###end p 33
###begin p 34
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 277 278 277 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1000 1001 1000 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1452 1456 1452 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">1(b)</xref>
###xml 1458 1459 1458 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">2</xref>
###xml 1465 1466 1465 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">3</xref>
###xml 1523 1525 1523 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1643 1644 1643 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 66 72 <span type="species:ncbi:9796">horses</span>
###xml 135 141 <span type="species:ncbi:9796">horses</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
###xml 536 542 <span type="species:ncbi:9796">horses</span>
###xml 547 551 <span type="species:ncbi:10116">rats</span>
###xml 1325 1330 <span type="species:ncbi:9606">human</span>
###xml 1331 1338 <span type="species:ncbi:9606">patient</span>
###xml 1434 1442 <span type="species:ncbi:9606">patients</span>
###xml 1736 1741 <span type="species:ncbi:9606">human</span>
Recently, CRALBP was identified as a novel uveitis autoantigen in horses using a 2D Western blot approach [1]. Reactivity of sera from horses suffering from spontaneous ERU included the known autoantigens S-Ag and IRBP and two novel autoantigens, namely, recoverin and CRALBP [1]. Previously, CRALBP had been described only in association to genetic mutations causing retinal degenerations [4, 6]. Given that CRALBP autoantibodies are present in human uveitis sera (this study) and that CRALBP induces recurrent uveitis in experimental horses and rats [1], CRALBP meets Witebsky's postulates regarding autoantigenicity [13]. Witebsky originally claimed three postulations to prove a relevant autoantigen. First, the target antigen must be identified; second, an autoimmune reaction against this autoantigen must be detectable; and third, the potential of the autoantigen to induce the respective disease must be proven. Rose et al. proposed three types of evidence to qualify as the third postulate [1]. These are direct evidence from transfer of pathogenic antibody or pathogenic T cells, indirect evidence based on reproduction of the autoimmune disease in experimental animals, and circumstantial evidence from clinical clues [13]. In view of the fact that in this study CRALBP was recognized as an uveitis autoantigen by human patient's serum and specific autoantibodies were detected in significant amounts in cohorts of uveitis patients (Figures 1(b), 2, and 3), the first two of Witebsky's postulates are fulfilled [13]. As the uveitogenic potential of CRALBP has already been demonstrated in two different experimental animal species [1], this again meets the Witebsky's postulates and suggests CRALBP as a true autoantigen for human autoimmune uveitis, accomplishing the third postulate.
###end p 34
###begin p 35
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 495 506 495 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1(c)</xref>
###xml 507 511 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">1(f)</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1216 1217 1216 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 273 279 <span type="species:ncbi:9606">humans</span>
###xml 397 402 <span type="species:ncbi:9606">human</span>
###xml 583 589 <span type="species:ncbi:9796">horses</span>
###xml 1199 1203 <span type="species:ncbi:10116">rats</span>
###xml 1208 1214 <span type="species:ncbi:9796">horses</span>
The morphological changes in the retina following CRALBP-induced uveitis in animals show several distinct histological features, which provide researchers familiar with the histopathology of human uveitis a further opportunity to confirm or reject CRALBP as autoantigen in humans from clinical clues (circumstantial evidence). Immunohistochemical evaluation of CRALBP expression pattern in normal human eyes confirmed strong expression in Mueller glial cells [4] through coexpression with GFAP (Figure 1(c)-1(f)). A predominant histopathological finding in CRALBP-induced uveitis in horses was the marked destruction of retinal architecture with rather minor infiltration of inflammatory cells compared to S-Ag or IRBP-induced uveitis [1]. Major changes involved disorganization of Mueller glial cells with fractional destruction accompanied by marked upregulation of glial acidic fibrillary protein and concurrent downregulation of glutaminsynthetase [1], indicating Mueller glial cell proliferation [14]. Additionally, overexpression of VEGF, a major cytokine causing vascular leakage and angiogenesis, could be demonstrated in retinal vessels and Mueller glial cells in CRALBP-induced uveitis in rats and horses [1].
###end p 35
###begin p 36
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 990 991 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 631 639 <span type="species:ncbi:9606">patients</span>
###xml 982 988 <span type="species:ncbi:9796">horses</span>
Autoimmune uveitis is a T cell-mediated disease driven by CD4+T cells with a Th1 phenotype [15] and can be induced successfully by adoptive transfer of antigen-specific CD4+T cells and T cell lines [16, 17]. Therefore, the ability of CRALBP to stimulate T cells of uveitis patients in vitro should be examined. However, a recurring problem of in vitro proliferation assays using peripheral blood derived lymphocytes (PBL) is that responses to autoantigens are rarely detected [8, 18]. Predominantly weak responses to autoantigens were, for example, also reported in the blood of multiple sclerosis [19] or rheumatic arthritis [20] patients. The low frequency of antigen-specific peripheral blood lymphocytes even in advanced cases of uveitis has been discussed as one reason for poor results in these proliferation assays [21]. This hypothesis is underlined by a considerably increased frequency and far stronger response of intravitreal lymphocytes compared to PBL in ERU diseased horses [8].
###end p 36
###begin p 37
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1099 1100 1099 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 1053 1059 <span type="species:ncbi:9796">horses</span>
Another aspect of CRALBP autoreactivity in uveitis patients and the few control subjects could focus on the predictive value of this immune reaction. Recent studies in other autoimmune diseases clearly support the potential of foretelling the development of the autoimmune disease when autoantibodies to a number of autoantigens are already present in the preclinical phase [10]. Type I diabetes is one such example and well studied. The presence of autoantibodies against three different diabetes autoantigens has a high predictive value for developing diabetes between  and  in the general population, which increases to  in first-degree relatives [10, 22-24]. It has also been reported that the autoimmune process precedes overt clinical symptoms for many months or years [10]. Therefore, the four CRALBP autoantibody-positive healthy subjects included in this study will be followed on their immune response and health status, since they could be at risk to develop uveitis in the future. Similarly, the CRALBP autoantibody-positive healthy control horses from the first CRALBP detection study [1] are currently monitored.
###end p 37
###begin p 38
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
A dynamic epitope spreading cascade may exist in spontaneous ERU cases [25] as well as in human uveitis patients [7]. Evidence for the involvement of CRALBP in the spreading cascade was established in ERU cases [1], and therefore CRALBP should now also be included in future studies on epitope spreading in human uveitis patients.
###end p 38
###begin p 39
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
Given that CRALBP function is not fully understood to date [26] and ligands in nonretinal tissues have yet to be identified [4], it is not difficult to assume several yet undetected roles of CRALBP that could be of further interest in association with uveitis.
###end p 39
###begin title 40
5. CONCLUSIONS
###end title 40
###begin p 41
###xml 60 65 <span type="species:ncbi:9606">human</span>
Our findings suggest that CRALBP is a novel autoantigen for human autoimmune uveitis that merits further investigations.
###end p 41
###begin title 42
ACKNOWLEDGMENTS
###end title 42
###begin p 43
###xml 344 349 <span type="species:ncbi:9606">human</span>
This work was supported by Deutsche Forschungsgemeinschaft (DFG) SFB 571 (to C. Deeg) as well as by the EU 6th FW Grant EVI-GENORET (LSHG-CT-2005-512036 to M. Ueffing). The authors would like to thank Stephanie Schoeffmann, Sabine Mangold, and Hendrik van Gemmeren for excellent technical assistance, Dr. Siegfried Priglinger for providing the human eyes for fixation, and Dr. Falko Steinbach for critical discussions.
###end p 43
###begin article-title 44
###xml 66 72 <span type="species:ncbi:9796">equine</span>
Identification and functional validation of novel autoantigens in equine uveitis
###end article-title 44
###begin article-title 45
###xml 120 126 <span type="species:ncbi:9913">bovine</span>
Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina
###end article-title 45
###begin article-title 46
###xml 84 88 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens
###end article-title 46
###begin article-title 47
Focus on molecules: cellular retinaldehyde-binding protein (CRALBP)
###end article-title 47
###begin article-title 48
Cellular retinaldehyde-binding protein interacts with ERM-binding phosphoprotein 50 in retinal pigment epithelium
###end article-title 48
###begin article-title 49
Vitamin A metabolism in the retinal pigment epithelium: genes, mutations, and diseases
###end article-title 49
###begin article-title 50
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human S-antigen determinant recognition in uveitis
###end article-title 50
###begin article-title 51
###xml 57 63 <span type="species:ncbi:9796">equine</span>
Immune responses to retinal autoantigens and peptides in equine recurrent uveitis
###end article-title 51
###begin article-title 52
###xml 58 63 <span type="species:ncbi:9606">human</span>
Structural and functional characterization of recombinant human cellular retinaldehyde-binding protein
###end article-title 52
###begin article-title 53
Are we ready to predict and prevent endocrine/organ specific autoimmune diseases?
###end article-title 53
###begin article-title 54
Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy
###end article-title 54
###begin article-title 55
Autoantibodies as predictors of disease
###end article-title 55
###begin article-title 56
Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
###end article-title 56
###begin article-title 57
Proteomic profiling of primary retinal Muller glia cells reveals a shift in expression patterns upon adaptation to in vitro conditions
###end article-title 57
###begin article-title 58
Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies
###end article-title 58
###begin article-title 59
###xml 74 77 <span type="species:ncbi:10116">rat</span>
T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat
###end article-title 59
###begin article-title 60
Evidence for selective accumulation of V  8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens
###end article-title 60
###begin article-title 61
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen-first results
###end article-title 61
###begin article-title 62
###xml 153 157 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Does the frequency and avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis?
###end article-title 62
###begin article-title 63
HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis
###end article-title 63
###begin article-title 64
###xml 74 82 <span type="species:ncbi:9606">patients</span>
A novel method for the determination of T-cell proliferative responses in patients with uveitis
###end article-title 64
###begin article-title 65
###xml 82 90 <span type="species:ncbi:9606">children</span>
IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes
###end article-title 65
###begin article-title 66
Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY)
###end article-title 66
###begin article-title 67
Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington state diabetes prediction study
###end article-title 67
###begin article-title 68
###xml 47 53 <span type="species:ncbi:9796">equine</span>
Inter- and intramolecular epitope spreading in equine recurrent uveitis
###end article-title 68
###begin article-title 69
###xml 76 80 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
RPE65 is essential for the function of cone photoreceptors in NRL-deficient mice
###end article-title 69
###begin p 70
###xml 0 69 0 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Identification of CRALBP-autoantibodies with proteomic Western blots.</italic>
###xml 269 308 269 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRALBP expression in normal human eyes.</italic>
###xml 74 80 <span type="species:ncbi:9796">Equine</span>
###xml 219 224 <span type="species:ncbi:9606">human</span>
###xml 233 240 <span type="species:ncbi:9606">patient</span>
###xml 297 302 <span type="species:ncbi:9606">human</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
Identification of CRALBP-autoantibodies with proteomic Western blots. (a) Equine retinal proteome (pH gradient 3-11, silver staining) was separated on 2D gels and transferred to nitrocellulose membranes. (b) Serum from human uveitis patient detects CRALBP (encircled). CRALBP expression in normal human eyes. (c) Nomarski image of normal human retina (donor no. 6, male, age 49). (d) CRALBP expression (green) at Mueller glial cells. (e) GFAP expression (red) at Mueller glial cells. (f) Double labeling of CRALBP (green) and GFAP (red) clearly demonstrates colocalization (yellow) of CRALBP and GFAP at Mueller glial cells.
###end p 70
###begin p 71
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Representative Western blot signals at <inline-formula><mml:math id="M45"><mml:mrow><mml:mn>36</mml:mn><mml:mi>&#8201;</mml:mi><mml:mtext>kD</mml:mtext></mml:mrow></mml:math></inline-formula> obtained </italic>
###xml 49 79 49 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">against purified human CRALBP.</italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 338 345 <span type="species:ncbi:9606">patient</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 420 425 <span type="species:ncbi:9606">human</span>
Representative Western blot signals at  obtained against purified human CRALBP. Sera of human uveitis patients and healthy controls were tested on  Western blots. Lane 1: strong signal of healthy control, lane 2: healthy signal of healthy control, lanes 3 and 4: intermediate signal of uveitis patients, lane 5: healthy signal of uveitis patient, lane 6 and 7: strong signal of uveitis patients, lane 8: monoclonal anti-human recombinant CRALBP antibody (Cayman), lane 9: marker with respective molecular weights.
###end p 71
###begin p 72
###xml 0 52 0 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Frequency and intensity of human IgG autoantibodies </italic>
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">to CRALBP.</italic>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 421 429 <span type="species:ncbi:9606">patients</span>
Frequency and intensity of human IgG autoantibodies to CRALBP. White circles represent healthy individuals, grey circles human uveitis patients. Western blot signal intensities were quantified with Image Quant TL software, grayscale pixel intensity of bands is given as arbitrary units (Y-axis). Negative reactions are dispatched below cutoff line. CRALBP autoantibodies occurred significantly more frequently in uveitis patients as in control group (compared by chi-square test, significance level ).
###end p 72

